HopeStage
Back to all studies
CompletedNCT02360319

Long-Acting Injectable Antipsychotic or Clinician’s Choice Early in Schizophrenia

About this titleRead the official source — NCT02360319
Medication studyAges 18–35United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 35 years. Other eligibility criteria applied.

Listed locations
Tucson and 38 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 11, 2014
Recruitment status
Completed
Enrollment listed in the registry
489
Sponsor
Vanguard Research Group
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 35 Years
Official registry ID
NCT02360319
Official title
Show the full official title

A Cluster Randomized, Multi-center, Parallel-group, Rater-blind Study Comparing Treatment With Aripiprazole Once Monthly and Treatment as Usual on Effectiveness in First Episode and Early Phase Illness in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Tucson · Granada Hills · Palo Alto

35 more locations
  • Fort Lauderdale
  • Gainesville
  • Jacksonville
  • Leesburg
  • St. Petersburg
  • Tallahassee
  • West Palm Beach
  • Atlanta
  • Augusta
  • Chicago
  • Granite City
  • Iowa City
  • Fall River
  • Worcester
  • Ann Arbor
  • East Lansing
  • Grand Rapids
  • Kalamazoo
  • Mount Pleasant
  • Muskegon
  • St Louis
  • Omaha
  • Manchester
  • Nashua
  • Paramus
  • Durham
  • Cincinnati
  • Wooster
  • Eugene
  • Huntingdon
  • Beaumont
  • Houston
  • Longview
  • San Antonio
  • Salt Lake City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Vanguard Research Group.

Did this study involve medication?

Yes. The study involved medication, including Any FDA approved antipsychotic agent and aripiprazole long acting injectable formulation.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 35 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies